An effective candidate for the treatment of acute lung injury has been found. In the case of acute lung injury, there has been no treatment method other than a ventilator and conservative treatment, and the discovery of this candidate is expected to increase the possibility of pharmacological treatment for acute lung injury patients.
Yonsei University Yongin Severance Hospital Respiratory Allergy Prof. Eunhye Lee, Severance Hospital Respiratory System Prof. Park Moo-seok, Otorhinolaryngology Prof. Jae-Young Choi, Yonsei University College of Pharmacy Prof. Revealed that it has newly identified. The research results were published in the latest issue of the international journal Theranostics (IF 8.579).
Acute lung injury is caused by various causes such as severe medical stress such as sepsis, shock, bleeding, pancreatitis, trauma, or surgical damage. Acute lung injury in intensive care patients is a frequently occurring lung complication. Among them, acute respiratory distress syndrome, which is the most serious, has a mortality rate of 30-50%. However, despite many studies and advances in the treatment of critically ill patients, the treatment of acute respiratory distress syndrome is limited to ventilators and conservative treatments.
The research team investigated the role of the’fendrin’ protein through a mouse model of pneumonia-induced acute lung injury injected with lipopolysaccharide (LPS), a representative bacterial toxin, and the effect of the’fendrin inhibitor’ developed by Professor Nam Gung-wan of Yonsei University College of Pharmacy. Confirmed.
‘Fendrin’ protein is a protein that exchanges ions in various types of cells in the body, and is known to exist in epithelial cells of the inner ear, thyroid and airways. Among respiratory diseases, it is known that the expression of pendrin is increased in patients with asthma, chronic obstructive disease, and allergic rhinitis.
As a result of the study, we found that pendrin was overexpressed in the airways and alveoli of a mouse model of acute lung injury injected with the bacterial toxin LPS.
In addition, the research team confirmed that lung damage was reduced by injecting a pendrin inhibitor (YS-01) into an animal model that showed a phenomenon in which pendrin was overexpressed. When administered with a’fendrin inhibitor’, the influx of thiocyanic acid and hypothiocyanate ions into the alveolar lumen is reduced, and lung damage is suppressed by inhibition of NF-kB, a protein involved in inflammatory reaction, and reduction of inflammatory cytokines Presented.
The research team also analyzed bronchoalveolar lavage fluid in 41 patients with pneumonia-induced acute respiratory distress syndrome and 25 patients without lung injury, and confirmed the phenomenon of overexpression of pendrin in patients suffering from acute respiratory distress syndrome. Confirmed.
Prof. Eun-Hye Lee and Prof. Moo-Seok Park said, “Despite many studies, there were no effective drugs that can be used in acute lung injury. Through this study, pendrin present in the airways and lung epithelial cells is acute lung injury and acute breathing. “We have found that it can be an important therapeutic target for insufficiency syndrome.”
Professor Jae-young Choi added, “It is meaningful to draw more advanced results through joint research with the College of Pharmacy at Yonsei University. Through this study, we look forward to increasing the variety of treatments available for acute lung injury in the future.”
Meanwhile, this research was conducted with the support of the National Research Foundation of Korea. Reporter Jang Jong-ho [email protected] .
